Pulmonary fibrosis is a common consequence of numerous pulmonary diseases. The current therapeutic approaches for this condition are unsatisfactory. Feitai, a composite formula consisting of several herbs, is used in China as a folk remedy for treating patients with pulmonary tuberculosis. In this study, we extensively investigate the effects and mechanisms of Feitai on bleomycin (BLM)-induced pulmonary fibrosis in rats. One hundred and twenty male Sprague-Dawley rats were randomly divided into four groups, referred to as the saline-water, saline-Feitai, BLM-water, and BLM-Feitai groups. Following a single instillation of BLM (5 mg/kg) or saline, rats were orally administered Feitai at a dose of 3 g/kg body weight or sterilized distilled water once daily. Rats were killed at 7, 14, or 28 d post-BLM. Inflammatory cell count, protein concentration, and lactate dehydrogenase activity in bronchoalveolar lavage fluid were measured, and myeloperoxidase activity and lipid peroxide content in lung homogenates were analyzed. Treatment with Feitai inhibited lung fibrotic progression induced by BLM, as indicated by the decrease in lung hydroproline content and lung fibrosis score at 28 d post-BLM. This was accompanied by significant amelioration of BLM-induced body weight loss, lung edema, and inflammatory response during the development of lung injury in the acute phase. The results strongly indicate the beneficial effects of Feitai in protecting against BLM-induced pulmonary fibrosis. Furthermore, the inflammatory response and lipid peroxidation were inhibited by Feitai, suggesting that the effect of this formula on BLM-induced lung injury and fibrosis is associated with antiinflammatory and antioxidant properties.
Pulmonary fibrosis, the end-point of a heterogeneous group of disorders designated "lung diseases", is characterized by fibroblast proliferation and extracellular matrix remodeling, resulting in severe respiratory impairment. Pulmonary fibrosis currently affects up to 100000 people in the U.S.A. 1) Immunosuppressive therapy, the mainstay of the current approach to pulmonary fibrosis, is not particularly effective. [2] [3] [4] Therefore the development of successful strategies to prevent pulmonary fibrosis remains an urgent challenge.
The pulmonary fibrosis model in rodents induced by bleomycin (BLM) is widely used to study the mechanism of lung fibrosis and antifibrotic effects of numerous drugs. [5] [6] [7] [8] [9] [10] [11] Following intratracheal administration into the lungs of rats, BLM causes alveolar cell damage, inflammatory response, fibroblast proliferation and subsequent collagen content deposition. Lesions observed in the early stages of lung damage induced by BLM resemble chronic human fibrotic lung disease, both histologically and physiologically. [12] [13] [14] [15] [16] [17] [18] [19] [20] Interventions designed to limit the consequences of the inflammatory response [such as corticosteroids, anti-tumor necrosis factor (TNF)-a antibody, and anti-transforming growth factor (TGF)-b antibody] and to protect the lung from oxidant damage (such as Ginkgo biloba extract, 8) metalloporphyrin, 9) and N-acetylcysteine 10) ) are effective in suppressing BLM-induced pulmonary fibrosis. These findings suggest that inhibition of lung inflammation and lipid peroxidation may be employed as therapeutic strategies for pulmonary fibrosis in the clinic.
Feitai, a composite formula comprising the herbs Huangqin In the present study, we extensively investigated the effects of Feitai on BLM-induced pulmonary fibrosis in rats. Moreover, changes in biochemical and histopathologic parameters following BLM instillation are characterized to elucidate the role of Feitai during the development of pulmonary fibrosis.
MATERIALS AND METHODS

Chemicals and Reagents
Feitai, a prescription formulation, is a mixture of the extracts of five medical herbs ( Experimental Protocols One hundred and twenty rats weighing 200-250 g were randomly divided into the following four groups: saline-water; saline-Feitai; BLM-water; and BLM-Feitai. The first two control groups were injected intratracheally with saline in a volume of 2 ml/kg body weight and treated with sterilized distilled water or Feitai 3 g/kg body weight orally. Rats in the other two groups were received sterilized distilled water or Feitai 3 g/kg body weight once daily after an intratracheal injection of BLM solution. According to the results from a preliminary dose-response study of Feitai, we selected the dose of 3 g/kg body weight for this experimental protocol.
Intratracheal injection was performed under light chloralhydrate (40 mg/kg body weight) anesthesia. Briefly, the trachea was exposed and punctured with a 27-gauge needle via a small cervical skin incision and separation of the strap musles. BLM (5 mg/kg body weight, 2 ml/kg body weight) or saline was injected slowly. The day of intratracheal injection with BLM or saline was designated day 0. To investigate the time-course effect of Feitai, rats were euthanized 7, 14, or 28 d after BLM or saline administration. The lung vasculature was perfused free of blood by slowly injecting 50-80 ml of phosphate-buffered saline (PBS) into the right ventricle. The left lungs were removed from the trachea and hilar nodes and weighed. Half of the left lung was fixed in 4% phosphate-buffered paraformaldehyde for histopathologic preparation, while the other half was frozen in liquid nitrogen for homogenate preparation. Bronchoalveolar lavage fluid (BALF) was collected from the right lung as follows: PBS 3 ml was instilled three times and fluid was withdrawn from the right lung via a tracheal cannula. Routine recovery of BALF fluids did not differ significantly between animals with Ͼ70% of instilled volume recovered. The body weight of each animal was monitored every other day.
BALF Analysis
The total cell numbers and their proportion in BALF were examined immediately following lavage. The remainder of each sample was centrifuged at 1200ϫg for 15 min at 4°C. Cell pellets were smeared and stained with Giemsa solution for differential counting. Two hundred cells were counted for each sample and expressed as a percentage of the total cells recovered. The supernatant fractions were used to measure total protein concentration and LDH activity. The total protein concentration was determined using Coomassie brilliant blue G250 staining, and expressed as grams of protein per liter of BALF (g/l). LDH activity was assessed using a test reagent kit and determined as units per liter of BALF (U/l).
Lung Tissue Homogenate Preparation and Analysis Lung tissue samples were homogenized in cold Tris-HCl buffered saline (pH 7.4, 0.01 mol/l Tris-HCl, 0.0001 mol/l EDTA-2Na, 0.01 mol/l saccharose, 0.8% sodium chloride solution) three times at 4°C with a polytron homogenizer (10 s of homogenization at 10-s intervals). The tissue homogenate was 10% (w/v). After removing 0.1 ml of homogenates for the MPO activity assay, samples were centrifuged at 3000ϫg for 10 min at 4°C, and the supernatant was used to measure LPO levels and collagen content.
MPO activity in the homogenates was assayed with a microplate reader (BIORAD Model 550) using the MPO test kit. Changes in absorbance at 450 nm were measured with the microplate reader. MPO activity is expressed as units per gram of tissue (U/g). One unit per gram of tissue is defined as MPO degrading 1 mmol peroxide at 37°C per gram of tissue.
LPO content was determined according to the thiobarbituric acid method with the malondialdehyde test kit. Results are expressed as nmol LPO per gram of protein of lung tissue (nmol/g).
Collagen content of the lung is presented as the index of hydroxyproline concentration estimated using the test kit. Colored products were measured at 550 nm using the microplate reader. Data are expressed as micrograms of hydroxyproline per gram of protein in lungs (mg/g).
Histopathologic Evaluation Rat lung tissues were fixed in 4% phosphate-buffered paraformaldehyde (pH 7.4) and processed for routine paraffin embedding. Serial sections (5 mM) were cut and stained with hematoxylin and eosin (H&E) and a modified Masson trichrome to assess the degree of fibrosis. The severity of alveolitis and fibrosis was blindly assessed semiquantitatively, according to criteria previously described by Szapiel et al. 21) Statistical Methods Data were entered into a database and analyzed using SPSS software. Group mean values and standard deviations were calculated. After homogeneitic analysis, homogeneous data were analyzed with one-way analysis of variance and a post hoc test of least significant difference (LSD). To determine intergroup differences, heterogeneous data were analyzed using the independent samples t-test. Cell differential data in BALF and alveolitis and fibrosis scores of lung tissue were evaluated using the MannWhitney test. Differences in the severity of lesions between BLM-water and BLM-Feitai treated rats were evaluated for significance using Fisher's exact test. Differences in the body weight between groups were assessed using the multivariate process. The statistical significance level was set at pϽ0.05.
RESULTS
Body Weight Changes
The body weights of all treated rats were evaluated during the study period. Changes in body weight after BLM treatment are shown in Fig. 1 . BLM-Feitai-treated rats displayed less body weight loss than rats treated with BLM alone.
Wet Weights and Relative Weights of Lungs
The left lung was weighed and the relative weight (lung weight/body weight ϫ100%) was calculated for each animal. The increase in wet weight of the lung is one of the indices representing lung edema. As shown in Table 2 , the wet and relative weights of the lung increased more than three-fold 7 d after BLM treatment and decreased gradually thereafter. The in-636
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BALF Analysis Total and differential cell counts in BALF at each time point are presented in Fig. 2 . The total cell number was much higher in BLM-treated rats, compared with saline-treated rats at 7, 14, and 28 d (pϽ0.01). A peak appeared at 7 d and was sustained up to 14 d, followed by a decrease. Administration of Feitai reduced the BLM-induced increase in total cell number in BALF during the experimental period. An increase in the percentage of polymorphonuclear leukocytes (neutrophils) and lymphocytes and a decrease in microphages were observed 7 and 14 d after BLM administration. There were no statistical differences in the proportion of cells in BALF between the BLM-water and BLM-Feitai groups at each time point. However, at all times, the absolute numbers of differential inflammatory cells were significantly reduced in the BLM-Feitai group compared with the BLM group (data not shown).
LDH activity in BALF represents the extent of damage to lung cells. LDH activity is a general marker of cell damage. Following BLM instillation, LDH activity was significantly increased in BALF and peaked at 7 d (Fig. 3A) . Treatment with Feitai attenuated the BLM-induced increase in LDH activity in BALF, and normal levels were observed at 28 d. The data indicate that Feitai protects lung cells from damage induced by BLM.
Increased protein concentration in BALF is another important marker of alveolar edema in the acute phase. The protein concentration was significantly increased in BALF following BLM treatment. Protein levels peaked 7 d after BLM instillation and declined thereafter. Feitai treatment led to a reduction in the BLM-induced increase in protein content in alveoli, suggesting that the compound ameliorates lung edema (Fig. 3B) .
MPO Activity MPO activity in lung tissue was measured to determine neutrophil sequestration, which reflects a severe degree of inflammation in the lung after BLM instillation. As shown in Fig. 4A , lung MPO activity rapidly increased following BLM instillation. High levels were observed 7 to 14 d post-BLM. Feitai significantly attenuated the BLM-induced increase in MPO activity at 7 and 14 d. There were no statistical differences at 14 and 28 d in MPO activity between the BLM-Feitai and the control groups. These results showed that treatment with Feitai relieved the early inflammatory response in the lung induced by BLM.
LPO Content The LPO content in lung was increased in the BLM-water group at each time point, peaking 7 d post- BLM and gradually declining thereafter, without reaching normal levels by the end of the study. Increased lipid peroxidation induced by BLM was consistent with the inflammatory changes in the lung. The LPO level in the BLM-Feitai group was lower than that in the BLM-water group (pϽ0.05), as depicted in Fig. 4B .
Hydroxyproline Content The hallmark of fibrosis is collagen deposition. The measurement of hydroxyproline is an efficient index of fibrosis, since collagen contains significant amounts of the amino acid. The effect of Feitai on pulmonary fibrosis was assessed by evaluating the hydroxyproline content of lung homogenates 7, 14, and 28 d following BLM intratracheal administration (Fig. 4C) . At 28 d, the hydroxyproline content of the lungs in the BLM-water group increased approximately two-fold compared with that in the control groups. Treatment with Feitai led to a significant reduction in the hydroxyproline content compared with that in the BLM-water group (pϽ0.05), indicating the beneficial effects of the Feitai formula in protecting against pulmonary fibrosis induced by BLM.
Histopathologic Findings To elucidate the histopathologic changes associated with BLM-induced lung fibrosis and the efficacy of Feitai, left lungs from the saline-water, saline-Feitai, BLM-water and BLM-Feitai groups were collected 7, 14, and 28 d after BLM instillation. Sections were stained with H&E and Masson's trichrome for collagen identification. Sections from the control groups displayed normal structure and no pathologic changes under a light microscope. In the BLM-water group at 7 d, severe edema, large amounts of inflammatory cells including neutrophils and lymphocytes in both alveoli and interstitium, and damaged endothelia and alveolar epithelia cells were observed (data not shown). Treatment with Feitai resulted in significant attenuation of these histopathologic findings. At 14 d post-BLM, foci of collagen deposition and fewer inflammatory changes were observed (data not shown). Furthermore, at 28 d, marked histopathologic changes, such as large fibrous areas, collapsed alveolar spaces, and traction bronchiectasis in the subpleural and peribronchial regions, were seen. Although fibrotic lesions were observed in the BLM-Feitai group, the extent of fibrosis was markedly less severe compared with that in the BLM-water group (Fig. 5) .
To confirm the effects of Feitai on the histopathology of BLM-induced lung injury and fibrosis, the overall grades of inflammatory and fibrotic changes of the lungs were estimated by numerical scoring at 7, 14, and 28 d. The scores of alveolitis and fibrosis in the lung sections of the BLM-Feitai group were significantly decreased compared with those in the relevant BLM-water group (pϽ0.01; Table 3 ).
DISCUSSION
An ideal therapeutic strategy for pulmonary fibrosis in the clinic has yet to be established. There is a vital need for an agent with antifibrotic properties and acceptable side effects. [2] [3] [4] 22) The acute toxicity data in our laboratory show that the maximum tolerated dose of oral Feitai is greater than 20 g/kg body weight in mice, consistent with the requirement for lower toxicity in long-term clinical treatment for pulmonary tuberculosis. Feitai may have the characteristics of a complex remedy, since the compound is prepared from several Chinese herbs.
Our present studies show that treatment with Feitai inhibits lung fibrotic progression induced by BLM, as determined by the decrease in lung hydroxyproline content and histopathologic lung fibrosis scores at 28 d post-BLM instillation, accompanied by significant amelioration of BLM-induced body weight loss, lung edema, and inflammatory response during the development of lung injury in the acute phase. The data suggest that Feitai may be employed as a successful therapeutic candidate agent for attenuating lung fibrosis.
The inflammatory response is the initial response following injury challenges in the lung. The response includes migration and activation of both resident and circulating inflammatory cells and the production of cytokines and growth factors. Chemoattractant agents derived from the injured lung tissue initially recruit inflammatory cells, including neutrophils, macrophages, and lymphocytes, into the alveolar space. Inflammatory cells release cytokines, chemokines and growth factors, such as interleukin (IL)-1 and -4, fibroblast growth factor (FGF)-b, TGF-b, TNF-a, gamma interferon (IFN)-g, insulin-like growth factor (IGF)-1, heparin binding epidermal-like growth factor (HB-EGF), and platelet-derived growth factor (PDGF), and secrete matrix remodeling proteases, principally the matrix metalloproteinases (MMPs). 23) Meanwhile, injury causes increased permeability of the pulmonary epithelium and endothelium, resulting in extravasation of plasma proteins and ultimately extracellular matrix remodeling and fibrin deposition in the alveolar lumen and interstitium. 11, 24) Cytokines released by inflammatory cells are important for fibrogenesis (e.g., IL-6, TNF-a, IL-1, PDGF, and TGF-b]. 25) Those results suggest that inflammatory cell recruitment serves to propagate fibrosis. Similarly, the capacity to ameliorate fibrotic lesions is often associated with attenuation of inflammatory cell recruitment. The first line of therapy, specifically the use of corticosteroids and other immunosuppressive drugs, is based on this hypothesis. In the present animal model, treatment with Feitai significantly ameliorated BLM-induced lung edema and inflammation of the lung in rats, along with pulmonary fibrosis. These findings imply that the effect of Feitai on pulmonary fibrosis is associated with its antiinflammatory property.
The overproduction of superoxide and intermediates of free-radical reactions is an important amplifying system, which plays a key role in BLM-induced pulmonary inflammation and fibrosis. The lung is selectively affected by BLM, since this tissue lacks the enzyme hydrolyzing the baminoalanine moiety of BLM, which prevents the metabolite from binding metals such as iron. 26) Thus the toxicity of BLM is related to redox cycling of an iron-BLM complex, which in turn catalyzes the formation of reactive oxygen species. 27, 28) Free radicals target biomacromolecules, such as DNA, protein, and lipids, with the ultimate progression of lipid peroxidation. On the other hand, activated inflammatory cells induced by cell damage in the lung release reactive oxygen and nitrogen species are also involved in the oxidant damage of the lung induced by BLM. 29) BLM cytotoxicity is prevented by superoxide dismutase in vitro, 30) and a number of antioxidants protect rodents from pulmonary injury and fibrosis. [8] [9] [10] Using this pulmonary fibrosis model, Feitai significantly decreased BLM-enhanced levels of LPO, suggesting that some antioxidants present in the formula may be involved in the protective mechanism against pulmonary fibrosis.
Numerous studies additionally demonstrated that injured/activated alveolar epithelial cells at the distinguishable early stage of alveolitis are an important factor in the progression of lung fibrosis. 22, 31, 32) In the present analyses, BLM-water-treated rats exhibited sustained cell injury in the lung microenviroment. Treatment with Feitai attenuated cell damage triggered by BLM, as determined by the changes in LDH activity in BALF. Further studies are required to address the possibility that the antifibrotic effects of Feitai are mediated, in part, through protecting epithelial cells.
In summary, our results demonstrate beneficial effects of Feitai against pulmonary fibrosis induced by BLM. Furthermore, lipid peroxidation and the inflammatory response are inhibited by Feitai, suggesting that the effect of this formula on BLM-induced lung injury and fibrosis is associated with its antioxidant and antiinflammatory properties. Treatment  BLM  0  I  II  III  Average score  0  I  II  III  Average score   Saline-water  7 
